Mazdutide vs Tirzepatide: GLP-1/Glucagon vs GIP/GLP-1 Dual Agonists

Introduction#

Mazdutide and tirzepatide are both dual incretin agonists that surpass GLP-1 monotherapy for weight loss, but they employ different receptor combinations to achieve their effects. Tirzepatide pairs GIP with GLP-1 signaling, while mazdutide pairs glucagon with GLP-1 signaling. This fundamental mechanistic difference has implications for metabolic effects, hepatic fat handling, and potentially which patient populations benefit most. Comparing these two defines the current frontier of multi-receptor obesity pharmacology.

Quick Comparison#

Mechanism of Action Comparison#

Mazdutide#

Mazdutide (IBI362/LY3305677) is a synthetic oxyntomodulin analog that activates both the GLP-1 receptor and the glucagon receptor. The 33-amino acid peptide includes an Aib substitution at position 2 for DPP-4 resistance and a C20 fatty diacid at lysine-20 for albumin binding and once-weekly pharmacokinetics.

The GLP-1 receptor component provides appetite suppression through hypothalamic satiety circuits, delayed gastric emptying, and glucose-dependent insulin secretion. The glucagon receptor component adds energy expenditure enhancement through hepatic thermogenesis, direct hepatic fat oxidation through fatty acid beta-oxidation, and lipid mobilization from both hepatic and adipose tissue. The GLP-1-mediated glucose lowering offsets the hyperglycemic tendency of glucagon receptor activation.

This glucagon component is particularly relevant for metabolic liver disease. Glucagon receptor agonism directly promotes hepatic fat clearance, making mazdutide mechanistically suited for MASH/NASH-related metabolic goals beyond weight loss alone.

Tirzepatide#

Tirzepatide is a 39-amino acid synthetic peptide that activates both the GIP receptor (GIPR) and the GLP-1 receptor. Like mazdutide, it uses a C20 fatty diacid for albumin binding and weekly pharmacokinetics, but the second receptor target is GIP rather than glucagon.

GIP receptor agonism provides insulin sensitization in adipose tissue, enhanced nutrient-stimulated insulin secretion (complementing the GLP-1 component), potential direct CNS effects on appetite regulation, and improved adipose tissue lipid handling and metabolism. The GLP-1 component provides the same appetite suppression, gastric emptying delay, and glucose-dependent insulinotropic effects as in semaglutide and mazdutide.

The GIP/GLP-1 combination was counterintuitive when first proposed, as GIP was traditionally associated with fat storage and obesity. However, pharmacological GIP receptor agonism at high doses appears to produce weight loss rather than gain, possibly through desensitization of adipocyte GIP signaling or through central appetite effects. The SURMOUNT-1 trial validated this approach with 20.9% body weight reduction.

Evidence and Research Comparison#

Mazdutide Research#

Mazdutide was approved in China in June 2025 for weight management, making it the first GLP-1/glucagon dual agonist to receive regulatory approval anywhere:

• Phase 3 obesity (China): Up to 20.1% body weight reduction at the 9 mg dose over 60 weeks; dose-dependent response across 3, 6, and 9 mg arms
• Phase 3 T2D: HbA1c reductions up to 2.15% versus placebo in Chinese population trials
• Phase 1b/2 data: Earlier dose-finding studies establishing the efficacy and tolerability profile
• Global development: Ongoing clinical trials outside China, but no FDA approval or submission as of early 2026
• Limitation: Primary clinical data from Chinese population; cross-ethnic generalizability to be confirmed in global trials

Tirzepatide Research#

Tirzepatide has the most comprehensive Phase 3 program of any dual agonist:

• SURPASS program: Seven Phase 3 trials in type 2 diabetes; SURPASS-2 showed superiority over semaglutide 1 mg for HbA1c reduction and weight loss
• SURMOUNT program: Multiple Phase 3 trials in obesity; SURMOUNT-1 demonstrated 15%, 19.5%, and 20.9% body weight reduction at 5, 10, and 15 mg respectively over 72 weeks
• FDA approvals: Mounjaro (T2D, May 2022) and Zepbound (obesity, November 2023)
• Cardiovascular outcomes: SURPASS-CVOT in progress to evaluate cardiovascular safety and efficacy
• Global availability: Approved in US, EU, and numerous international markets

Side Effects and Safety Comparison#

Mazdutide Side Effects#

• GI effects: Nausea, diarrhea, and vomiting consistent with GLP-1 class; dose-dependent frequency
• Glucagon-specific considerations: Potential for hepatic glucose output increase, particularly relevant in diabetic populations; mitigated by the GLP-1 component
• Safety database: Primarily from Chinese Phase 3 trials; real-world post-marketing data accumulating since June 2025 approval
• Limitation: Limited data on long-term safety, rare adverse events, and cross-ethnic safety profile

Tirzepatide Side Effects#

• GI effects: Nausea (12-24% depending on dose), diarrhea, vomiting, constipation; typically most prominent during dose escalation
• Serious risks: Thyroid C-cell tumor boxed warning (rodent studies); pancreatitis risk; gallbladder events
• Safety database: Large, diverse population across SURPASS and SURMOUNT programs; growing real-world safety data from millions of prescriptions
• Dose escalation: Gradual monthly increases (2.5 mg starting dose) help manage GI tolerability

Dosing and Administration Comparison#

Mazdutide Dosing#

Tirzepatide Dosing#

Use Case Recommendations#

Choose Mazdutide When:#

• Hepatic fat reduction is a specific metabolic goal, where glucagon-mediated fat oxidation provides a differentiated mechanism
• Chinese/Asian market access is relevant, as mazdutide is approved and available in China
• GLP-1/glucagon dual mechanism is preferred for patients who may benefit from energy expenditure enhancement alongside appetite suppression
• MASH/metabolic liver disease is a co-occurring condition alongside obesity

Choose Tirzepatide When:#

• Maximum evidence-based weight loss is the goal, with 20.9% demonstrated in SURMOUNT-1
• Type 2 diabetes management requires proven glycemic control, with superiority over semaglutide in SURPASS-2
• FDA-approved treatment is needed in the US or EU markets
• Comprehensive dose flexibility is desired across six dose levels for individualized titration

Can They Be Combined?#

Combining mazdutide with tirzepatide is not rational, as both contain GLP-1R agonist activity. The redundant GLP-1 stimulation would likely increase GI side effects without proportional benefit. The different second-receptor components (glucagon vs GIP) make the combination pharmacologically complex with no theoretical or preclinical rationale.

The more relevant research question is whether triple receptor agonism (GIP + GLP-1 + glucagon) combining elements of both approaches could outperform either dual agonist. Retatrutide, a triple agonist targeting all three receptors, is being investigated to address this question, with early data suggesting weight loss of up to 24% in Phase 2.

For other metabolic comparisons, see mazdutide vs semaglutide and semaglutide vs survodutide. Explore our GLP-1 saturation calculator for metabolic peptide pharmacokinetic modeling.

Verdict#

Tirzepatide is the current evidence leader among dual agonists with FDA approval, the highest published weight loss data of any approved obesity therapeutic (20.9% in SURMOUNT-1), and a comprehensive global clinical program. Mazdutide represents an alternative dual agonist strategy using glucagon rather than GIP as the second receptor target, offering a differentiated mechanism for hepatic fat reduction and energy expenditure enhancement.

Tirzepatide's advantages are clear in evidence volume, global regulatory status, and demonstrated weight loss magnitude. Mazdutide's potential advantages lie in its glucagon component, which directly targets hepatic steatosis and may prove particularly valuable for patients with MASH or metabolic liver disease. Both represent significant advances over GLP-1 monotherapy. The question is not which dual agonist approach is universally better, but which second-receptor mechanism best serves specific patient populations and metabolic goals.

Further Reading#

• Mazdutide Overview and Research Guide
• Mazdutide Side Effects
• Mazdutide Dosing Protocols
• Tirzepatide Overview and Research Guide
• Tirzepatide Side Effects
• Tirzepatide Dosing Protocols